INNER GLOW™ SOL DEFENSE: The only gummy clinically proven1,2 to enhance sun protection—now part of a growing sun support line
Research proven1,2 Sol Defense Polypodium Gummies anchor a growing portfolio, now joined by a 500mg niacinamide capsule to broaden evidence based sun support options for dermatologists. Presented by Inner GlowTM Vitamins
INNER GLOW™ SOL DEFENSE:
The ONLY research proven1,2 UV-protection gummy.
Redefining Photoprotection for Today’s Patients
UV radiation remains the primary driver of skin cancer, yet sunscreen alone often falls short in real world use. Adherence challenges reduce effectiveness, increasing the risk of erythema, photoaging, and skin cancer. Inner Glow developed the polypodium powered Sol Defense line to complement topical SPF with an evidence-based approach that helps dermatologists better tailor photoprotection to each patient’s lifestyle and risk profile: Sol Defense Gummies for easy, everyday sun support in ages 3+; Age Defense for targeted support against melasma; and Sol Defense Pro with 500mg of Niacinamide for higher-risk patients.
At the core of our Sol Defense line is PolyLeucora™ Technology, a leaf-specific, aqueous 10:1 extract of Polypodium leucotomos that concentrates naturally occurring antioxidants while preserving bioactivity. This targeted extraction supports key cellular defense pathways involved in UV-induced oxidative stress, delivering consistent, clinically meaningful photoprotection.
The Only Clinically Proven UV-Protection Gummy
Inner Glow Sol Defense Gummies lead the category as the only UV protective gummy supported by clinical research. Each serving delivers a 280 mg dose of Polypodium leucotomos with niacinamide in a convenient format.
Clinical studies show:
improvements in MED (minimal erythema dose) and reductions in erythema intensity 1,2
use in patients ages 3 and older.3,4
- adjunctive use in photosensitive disorders such as polymorphous light eruption (PMLE).5
Advanced Systemic Photoprotection for Patients Who Need More
For patients with heightened sun sensitivity or extensive UV damage, Inner Glow is expanding its portfolio with Sol Defense Pro capsules, launching Spring 2026. This professional-grade formulation combines PolyLeucora Technology with 500 mg Niacinamide and Astaxanthin to address three distinct stages of UV-induced cellular stress: DNA repair, oxidative signaling, and membrane lipid peroxidation. These ingredients are complementary, not redundant, providing higher-level systemic support for patients who require maximum protection.
Bring next-generation photoprotection to your practice
Bring Sol Defense Gummies and Sol Defense Pro into your practice today. Sign-up below to request samples and provide your patients with research proven protection.
Click here to order your sample!
Please note that we can only ship samples within the United States at this time.
References:
1. Hussain A, Thakker S, Galaria N. Effectiveness of an oral supplement containing Polypodium leucotomos in enhancing sun protection: a clinical evaluation of minimal erythema dose pre- and post-consumption. Arch Dermatol Res. 2025;317(1):580. Published March 17, 2025. doi:10.1007/s00403-025-04055-8
2. Sach S, Thakker S, Hussain A. The impact of oral Polypodium supplementation on biologic photocapacity. J Am Acad Dermatol. 2025;93(3 suppl):AB320. Abstract presented at the American Academy of Dermatology (AAD) Annual Meeting; 2025.
3. Hakim C, Galaria A, Hussain A. Polypodium leucotomos gummy supplementation in the pediatric population: a retrospective series demonstrating favorable tolerability. Abstract presented at the Society for Pediatric Dermatology 50th Annual Meeting; July 23–26, 2025; Seattle, WA.
4. Hakim C, Galaria A, Hussain A. Evaluating the safety of a novel Polypodium leucotomos gummy supplement in pediatric atopic dermatitis. Abstract presented at VIrginia Dermatological Society;2025; Williamsburg, VA.
5. Hakim C, Galaria A, Hussain A. Adjunctive use of Polypodium leucotomos gummies in polymorphous light eruption and other photodermatoses. Abstract accepted for presentation at the American Academy of Dermatology (AAD) Annual Meeting; 2026.
